

Serial No. 10/628,933  
Attorney Docket No. IN01481KC


Presently Pending Claims

RECEIVED  
CENTRAL FAX CENTER

Language to be added has been **bolded** and **underlined**, while language to be deleted has been ~~**bolded and striken-through**~~.


SEP 15 2006

21. (Amended) A compound represented by the structural formula I




or a pharmaceutically acceptable salt or solvate thereof; wherein:

R<sup>1</sup> is



R<sup>2</sup> is selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkylketone, arylketone, alkyl, haloalkyl, cycloalkyl, **cycloheteroalkyl**, cycloalkylalkyl, alkylsulfonyl, arylsulfonyl, alkoxyalkyl, or amide;

R<sup>3</sup> is selected from the group consisting of **aryl**, 6-membered heteroaryl, **fluorenyl**; and **diphenylmethyl**, and 6-membered heteroaryl-N-



Serial No. 10/628,933  
Attorney Docket No. IN01481KC

optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup> and R<sup>15</sup>;

R<sup>4</sup> is 1-3 substituents selected from the group consisting of cycloheteroalkyl, -C(O)C<sub>3</sub>-C<sub>6</sub>cycloalkyl, -C(O)C<sub>3</sub>-C<sub>6</sub>cycloheteroalkyl, -(C<sub>1</sub>-C<sub>6</sub>)alkyl-N(R<sup>21</sup>)SO<sub>2</sub>R<sup>22</sup>, -(C<sub>1</sub>-C<sub>6</sub>)alkyl-C(O)NR<sup>23</sup>R<sup>24</sup>, -C(O)-(C<sub>4</sub>-C<sub>6</sub>)alkyl, R<sup>8</sup>-aryl-C(O), -C(O)N(H)OH, -(C<sub>4</sub>-C<sub>6</sub>)alkyl-N(R<sup>24</sup>)C(O)R<sup>22</sup>, -(C<sub>4</sub>-C<sub>6</sub>)alkyl-N(R<sup>21</sup>)CO<sub>2</sub>R<sup>22</sup>, -(C<sub>4</sub>-C<sub>6</sub>)alkyl-N(R<sup>21</sup>)C(O)NR<sup>23</sup>R<sup>22</sup>, -(C<sub>4</sub>-C<sub>6</sub>)alkyl-NR<sup>24</sup>R<sup>22</sup>, -(C<sub>4</sub>-C<sub>6</sub>)alkyl-NH<sub>2</sub>, -(C<sub>4</sub>-C<sub>6</sub>)alkylSO<sub>2</sub>NR<sup>24</sup>R<sup>22</sup> and -SO<sub>2</sub>NR<sup>21</sup>R<sup>22</sup>, wherein R<sup>4</sup> can be the same or different and is independently selected when there is more than one R<sup>4</sup> present;

R<sup>5</sup> is selected from the group consisting of H, arylalkyl, (C<sub>4</sub>-C<sub>6</sub>)alkyl, R<sup>8</sup>-aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, R<sup>8</sup>-heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)cycloalkyl, SO<sub>2</sub>-aryl, R<sup>8</sup>-aryl-SO<sub>2</sub>, -C(O)-(C<sub>4</sub>-C<sub>6</sub>)alkyl, -C(O)-(C<sub>4</sub>-C<sub>6</sub>)cycloalkyl, R<sup>8</sup>-aryl-C(O), -C(O)NR<sup>24</sup>R<sup>22</sup>, and -SO<sub>2</sub>NR<sup>21</sup>R<sup>22</sup>;

R<sup>6</sup> is H, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, or -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl;

R<sup>7</sup> is selected from the group consisting of aryl, substituted aryl, heteroaryl, alkyl, haloalkyl and cycloalkyl;

R<sup>8</sup> is 1, 2 or 3 substituents selected from the group consisting of H, halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CH<sub>3</sub>C(O), -CN, CH<sub>3</sub>SO<sub>2</sub>, CF<sub>3</sub>SO<sub>2</sub> and -NH<sub>2</sub>, wherein R<sup>8</sup> can be the same or different and is independently selected when there are more than one R<sup>8</sup> present;

R<sup>9</sup>, R<sup>10</sup> and B can be the same or different and are each independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, and -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl;

R<sup>11</sup> and R<sup>12</sup> can be the same or different and are each independently selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl, halogen, -NR<sup>19</sup>R<sup>20</sup>, -OH, CF<sub>3</sub>, -OCH<sub>3</sub>, -O-acyl, and -OCF<sub>3</sub>;

R<sup>13</sup> is selected from the group consisting of hydrogen, R<sup>11</sup>, H, phenyl, -NO<sub>2</sub>, -CN, -CH<sub>2</sub>F, -CHF<sub>2</sub>, -CHO, -CH=NOR<sub>18</sub>, -CH=NOR<sup>19</sup>, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, N(R<sub>20</sub>)CONR<sub>20</sub>R<sub>21</sub>, N(R<sup>20</sup>)CONR<sup>20</sup>R<sup>21</sup>, -NHCONH(chloro-(C<sub>1</sub>-C<sub>6</sub>)alkyl), -NHCONH((C<sub>3</sub>-C<sub>10</sub>)-cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl), -NHCO(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NHCOCF<sub>3</sub>, -NHCOOCF<sub>3</sub>, -NHSO<sub>2</sub>N((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -N(SO<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>, -NHCO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -

Serial No. 10/628,933  
Attorney Docket No. 1N01481KC

$\text{SR}^{22}$ ,  $-\text{SOR}^{22}$ ,  $-\text{SO}_2\text{R}^{22}$ ,  $-\text{SO}_2\text{NH}(\text{C}_1\text{-C}_6\text{ alkyl})$ ,  $-\text{OSO}_2(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $-\text{OSO}_2\text{CF}_3$ , hydroxy( $\text{C}_1\text{-C}_6$ )alkyl,  $-\text{CONR}^{19}\text{R}^{20}$ ,  $-\text{CON}(\text{CH}_2\text{CH}_2\text{-O-CH}_3)_2$ ,  $-\text{OCONH}(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $-\text{CO}_2\text{R}_{19}$ ,  $-\text{Si}(\text{CH}_3)_3$  and  $-\text{B}(\text{OC}(\text{CH}_3)_2)_2$ ;

$\text{R}^{14}$  is selected from the group consisting of ( $\text{C}_1\text{-C}_6$ )alkyl,  $-(\text{C}_1\text{-C}_6)$ haloalkyl  $-\text{NH}_2$  and  $\text{R}^{15}$ -phenyl;

$\text{R}^{15}$  is 1-3 substituents selected from the group consisting of hydrogen, ( $\text{C}_1\text{-C}_6$ )alkyl,  $-(\text{C}_1\text{-C}_6)$ haloalkyl,  $-\text{CF}_3$ ,  $-\text{CO}_2\text{R}^{20}$ ,  $-\text{CN}$ , ( $\text{C}_1\text{-C}_6$ )alkoxy and halogen; wherein  $\text{R}^{15}$  can be the same or different and is independently selected when there are more than one  $\text{R}^{15}$  present;

~~$\text{R}^{16}$  and  $\text{R}^{17}$  can each be the same or different and are each independently selected from the group consisting of hydrogen and ( $\text{C}_1\text{-C}_6$ )alkyl, or~~

~~$\text{R}^{16}$  and  $\text{R}^{17}$  together are a  $\text{C}_2\text{-C}_5$  alkylene group and with the carbon to which they are attached from a spiro ring of 3 to 6 carbon atoms;~~

$\text{R}^{19}$ ,  $\text{R}^{20}$  and  $\text{R}^{21}$  can each be the same or different and are each independently selected from the group consisting of H, ( $\text{C}_1\text{-C}_6$ )alkyl and ( $\text{C}_3\text{-C}_6$ )cycloalkyl;

$\text{R}^{22}$  is selected from the group consisting of ( $\text{C}_1\text{-C}_6$ )alkyl,  $-(\text{C}_1\text{-C}_6)$ haloalkyl, ( $\text{C}_2\text{-C}_6$ )hydroxyalkyl, ( $\text{C}_2\text{-C}_6$ )alkylene, ( $\text{C}_3\text{-C}_6$ )cycloalkyl, aryl and aryl( $\text{C}_1\text{-C}_6$ )alkyl-;

A is selected from the group consisting of H, ( $\text{C}_1\text{-C}_6$ )alkyl, and ( $\text{C}_2\text{-C}_6$ ) alkenyl.






























M is aryl or heteroaryl optionally substituted with  $\text{R}^4$ , wherein said aryl is phenyl; and

Q is CH or N, with the following proviso:

when  $\text{R}^1$  is phenyl, pyridyl, thiophenyl or naphthyl,  $\text{R}^2$  cannot be H,  $-(\text{C}_1\text{-C}_6)$ alkyl or  $-\text{C}(\text{O})-(\text{C}_1\text{-C}_6)$ alkyl.

22. (Amended) A compound having the structural formula I according to claim 21 wherein  $\text{R}^9$ ,  $\text{R}^{10}$  and B are H, A is  $-\text{CH}_3$ , and  $\text{R}^1$ ,  $\text{R}^2$  and  $\text{R}^3$  are as defined in the following table:

Serial No. 10/628,933  
Attorney Docket No. IN01481KC

#	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
4			
2			
3			
4			
5			
6			
7			
45			
47			
48			

Serial No. 10/628,933  
 Attorney Docket No. IN01481KC


49			
54			
55			
56			
57			
64			
112			
443			

23. (Amended) A compound according to claim 22 wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each represent:



Serial No. 10/628,933  
Attorney Docket No. IN01481KC

#	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
4			
2			
6			
47			
49			
56			
57			

24. (Amended) A compound according to claim 23 represented by the structural formulae:



Serial No. 10/628,933  
Attorney Docket No. IN01481KC



25. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 21.

26. (Previously presented) A pharmaceutical composition comprising one or more compounds of claim 24.

27. (Previously presented) The pharmaceutical composition according to claim 25 further comprising one or more pharmaceutically acceptable carriers.

28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.

29. (Previously presented) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds.

Serial No. 10/628,933  
Attorney Docket No. JN01481KC

30. (Previously presented) The pharmaceutical composition according to claim 26, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds.

31-40. (Previously canceled)